Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A partially-blinded, randomized, placebo and active controlled, ascending single-dose crossover phase I study to explore the safety, tolerability, pharmacokinetic and pharmacodynamic effects of PTH134 formulated with different concentrations of 5-CNAC in healthy postmenopausal women

Next Previous
Trial Profile

A partially-blinded, randomized, placebo and active controlled, ascending single-dose crossover phase I study to explore the safety, tolerability, pharmacokinetic and pharmacodynamic effects of PTH134 formulated with different concentrations of 5-CNAC in healthy postmenopausal women

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriparatide (Primary) ; Teriparatide
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis

Most Recent Events

  • 18 Oct 2009 Results reported at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
  • 10 Dec 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
  • 30 Jun 2008 Results are expected by the end of 2008, according to an Emisphere media release (9090628).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top